Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery (KIDPROAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01245595

Recruitment Status : Completed

First Posted : November 22, 2010

Results First Posted : June 8, 2015

Last Update Posted : June 8, 2015

Sponsor:

Information provided by (Responsible Party):

David Axelrod, Stanford University

Study Description

Brief Summary:

Children with congenital heart defects often need cardiac surgery with cardiopulmonary bypass (the "heart-lung machine"). Approximately 35 to 50% of these children will have "acute kidney injury," or damage to the kidneys, after the procedure. We currently have few medications to prevent this kidney injury. The hypothesis of this study is that giving aminophylline after heart surgery can decrease the acute kidney injury.

Condition or disease	Intervention/treatment	Phase
Acute Kidney Injury	Drug: Aminophylline Drug: Placebo	Not Applicable

Detailed Description:

Patients are randomized to receive aminophylline or placebo for 72 hours, in a blinded fashion. Serum theophylline levels monitor for safety of aminophylline dose. Goal theophylline levels is 5-7 mcg/ml. Laboratory results will be faxed directly to the pharmacy who will adjust subsequent aminophylline dosing to maintain appropriate theophylline levels. Urine output and serum creatinine levels will be monitored to assess acute kidney injury. Serum Neutrophil Gelatinase Associated Lipocalin (NGAL) levels will also be monitored.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	144 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Randomized Placebo Controlled Trial of Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery With Cardiopulmonary Bypass
Study Start Date :	November 2010
Actual Primary Completion Date :	May 2014
Actual Study Completion Date :	May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Surgery

Drug Information available for: Aminophylline

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Aminophylline Patients to receive aminophylline 5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours	Drug: Aminophylline 5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours Other Name: treatment
Placebo Comparator: Placebo Normal Saline Placebo	Drug: Placebo Normal Saline

Outcome Measures

Primary Outcome Measures :

Acute Kidney Injury Measured by Kidney Diseases: Improving Global Outcomes (KDIGO) AKI Serum Creatinine Criteria [ Time Frame: 5 days ]
Acute Kidney Injury measured by Kidney Diseases: Improving Global Outcomes (KDIGO) AKI Serum Creatinine criteria; KDIGO Stage is a measure of acute kidney injury.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	up to 18 Years (Child, Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Less than 18 years old, undergoing cardiac surgery with bypass
neonates must be at least 36 weeks gestational age

Exclusion Criteria:

History of arrythmia or seizure, on extracorporeal membrane oxygenation (ECMO) support, already taking aminophylline/theophylline, liver failure, sepsis, on renal replacement therapy

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01245595

Locations

Layout table for location information

United States, California
Lucile Packard Childrens' Hospital
Palo Alto, California, United States, 94304

Sponsors and Collaborators

Stanford University

Investigators

Layout table for investigator information

Principal Investigator:	david m axelrod, md	Stanford University

More Information

Layout table for additonal information

Responsible Party:	David Axelrod, MD, Clinical Assistant Professor, Stanford University
ClinicalTrials.gov Identifier:	NCT01245595
Other Study ID Numbers:	18977
First Posted:	November 22, 2010 Key Record Dates
Results First Posted:	June 8, 2015
Last Update Posted:	June 8, 2015
Last Verified:	June 2015

Keywords provided by David Axelrod, Stanford University:


Acute Kidney Injury (AKI) Cardiopulmonary bypass (CPB)

Additional relevant MeSH terms:

Layout table for MeSH terms

Acute Kidney Injury Wounds and Injuries Renal Insufficiency Kidney Diseases Urologic Diseases Aminophylline Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents	Respiratory System Agents Cardiotonic Agents Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Protective Agents

To Top